Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing Cardiovascular Risk

Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing Cardiovascular Risk

This CME/CE program aims to broaden healthcare professionals’ understanding of the complex nature of hyperlipidemia management. With a focus on low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)], this program addresses hyperlipidemia as a chronic and evolving condition that demands an integrated approach involving diet, lifestyle alterations, and innovative lipid-lowering treatments. The CME/CE program’s engaging “Clinical Counterpoints” format will guide participants through identifying patients at risk due to elevated Lp(a), applying the latest guidelines for managing high LDL-C levels, and enhancing healthcare team dynamics through shared decision-making and interprofessional patient care coordination.

  • Provider:National Lipid Association
  • Activity Link: https://www.lipid.org/
  • Start Date: 2025-05-30 05:00:00
  • End Date: 2025-05-30 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
    Nursing: 1.5 hours
    Pharmacy: 1.5 hours
  • MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: No
  • Activity Type: Live Course
  • CME Finder Type: Conference
  • Fee to Participate: Yes
  • Measured Outcome: Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Cardiovascular Disease, Internal Medicine
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.